- Home
- Publications
- Publication Search
- Publication Details
Title
Harnessing cytokines and chemokines for cancer therapy
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-07
DOI
10.1038/s41571-021-00588-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
- (2021) Geert R D'Haens et al. GUT
- Therapeutic Strategies for Targeting IL-1 in Cancer
- (2021) Adrian Gottschlich et al. Cancers
- Key chemokines direct migration of immune cells in solid tumors
- (2021) Karan Kohli et al. CANCER GENE THERAPY
- Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
- (2021) Melinda L. Telli et al. CLINICAL CANCER RESEARCH
- Pegilodecakin as monotherapy or in combination with anti‐PD ‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma ( RCC ): Final results of cohorts A, G, H, and I of IVY Phase I study
- (2021) Nizar M. Tannir et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
- (2021) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
- (2021) Karim Chamie et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer
- (2021) Owen Heath et al. Cancer Immunology Research
- Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer
- (2021) Sonia Missiroli et al. Cancers
- Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
- (2021) Pedro Bule et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes
- (2021) Paul B. Chapman JOURNAL OF CLINICAL ONCOLOGY
- Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).
- (2021) John M. Wrangle et al. JOURNAL OF CLINICAL ONCOLOGY
- ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.
- (2021) Valentina Boni et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
- (2021) Omid Hamid et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
- (2021) Margherita Turinetto et al. Frontiers in Oncology
- A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion
- (2021) Beatrice Malacrida et al. iScience
- Clinical significance of chemokine receptor antagonists
- (2020) Miao Miao et al. Expert Opinion on Drug Metabolism & Toxicology
- First-in-human phase I study of intraperitoneally administered interferon-activated autologous monocytes in platinum-resistant or refractory ovarian cancer.
- (2020) Christopher Browning Cole et al. JOURNAL OF CLINICAL ONCOLOGY
- Myc instructs and maintains pancreatic adenocarcinoma phenotype
- (2020) Nicole M Sodir et al. Cancer Discovery
- Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
- (2020) Eleni Maniati et al. Cell Reports
- Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
- (2020) Hanne Lind et al. Journal for ImmunoTherapy of Cancer
- Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
- (2020) Liuxue Sheng et al. BIOMEDICINE & PHARMACOTHERAPY
- Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
- (2020) Alain P. Algazi et al. CLINICAL CANCER RESEARCH
- Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
- (2020) Yoon-Koo Kang et al. CLINICAL CANCER RESEARCH
- Rationale for IL-15 superagonists in cancer immunotherapy
- (2020) Karin M. Knudson et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
- (2020) Georg Martin Haag et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- (2020) Bruno Bockorny et al. NATURE MEDICINE
- Translating IL-6 biology into effective treatments
- (2020) Ernest H. Choy et al. Nature Reviews Rheumatology
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
- (2020) Adi Diab et al. Cancer Discovery
- Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
- (2020) Brooke Benner et al. Drug Design Development and Therapy
- IL-15 in the Combination Immunotherapy of Cancer
- (2020) Thomas A. Waldmann et al. Frontiers in Immunology
- ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
- (2020) Jared E Lopes et al. Journal for ImmunoTherapy of Cancer
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
- (2020) Dmitriy Zamarin et al. CLINICAL CANCER RESEARCH
- TGFβ biology in cancer progression and immunotherapy
- (2020) Rik Derynck et al. Nature Reviews Clinical Oncology
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
- (2020) Byoung Chul Cho et al. Journal for ImmunoTherapy of Cancer
- The CCL5/CCR5 Axis in Cancer Progression
- (2020) Donatella Aldinucci et al. Cancers
- Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
- (2020) Joan How et al. Cancers
- Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
- (2020) Paolo Strati et al. Blood Advances
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- (2020) Catherine S. Grasso et al. CANCER CELL
- Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- (2020) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression
- (2020) Kristen Fousek et al. PHARMACOLOGY & THERAPEUTICS
- Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis
- (2020) Jun‐Lin Lu et al. Cancer Medicine
- Localized Interleukin-12 for Cancer Immunotherapy
- (2020) Khue G. Nguyen et al. Frontiers in Immunology
- Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
- (2020) Anne Montfort et al. CLINICAL CANCER RESEARCH
- Advances of CCR5 antagonists: From small molecules to macromolecules
- (2020) Baowen Qi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
- (2020) Ying Yang et al. Cancers
- Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
- (2020) David Spigel et al. Journal of Thoracic Oncology
- Fine-Tuning Cytokine Signals
- (2019) Jian-Xin Lin et al. Annual Review of Immunology
- Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics
- (2019) Karen Autio et al. Current Oncology Reports
- Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages
- (2019) C A Gomez-Roca et al. ANNALS OF ONCOLOGY
- The Immunobiology of the Interleukin-12 Family: Room for Discovery
- (2019) Elia D. Tait Wojno et al. IMMUNITY
- Shared and Distinct Functions of Type I and Type III Interferons
- (2019) Helen M. Lazear et al. IMMUNITY
- MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
- (2019) Philippe Alexandre Cassier et al. JOURNAL OF CLINICAL ONCOLOGY
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
- (2019) Elisabeth Perez-Ruiz et al. NATURE
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)
- (2019) Celeste Lebbe et al. EUROPEAN JOURNAL OF CANCER
- Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
- (2019) Shabnam Shalapour et al. IMMUNITY
- Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
- (2019) Marcus Noel et al. INVESTIGATIONAL NEW DRUGS
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
- (2019) William D Tap et al. LANCET
- Cancer modeling meets human organoid technology
- (2019) David Tuveson et al. SCIENCE
- Leukocyte Adhesion: Reconceptualizing Chemokine Presentation by Glycosaminoglycans
- (2019) Gerard J. Graham et al. TRENDS IN IMMUNOLOGY
- Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
- (2019) Shihong Zhang et al. Cancer Immunology Research
- Tuning the Tumor Myeloid Microenvironment to Fight Cancer
- (2019) Nadine S. Jahchan et al. Frontiers in Immunology
- A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
- (2019) Jeffrey Melson Clarke et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
- (2019) Toshihiko Doi et al. CLINICAL CANCER RESEARCH
- Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
- (2019) Aung Naing et al. LANCET ONCOLOGY
- Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
- (2019) Sumanta Pal et al. LANCET ONCOLOGY
- Modulators of CXCR4 and CXCR7/ACKR3 function
- (2019) Ilze Adlere et al. MOLECULAR PHARMACOLOGY
- Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
- (2019) Marijo Bilusic et al. Journal for ImmunoTherapy of Cancer
- Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
- (2019) U Dafni et al. ANNALS OF ONCOLOGY
- Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy
- (2019) Stephen K. Doberstein EXPERT OPINION ON BIOLOGICAL THERAPY
- Biology and therapeutic potential of interleukin-10
- (2019) Margarida Saraiva et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma
- (2019) Genmao Cao et al. MEDICINE
- Flip the coin: IL-7 and IL-7R in health and disease
- (2019) João T. Barata et al. NATURE IMMUNOLOGY
- Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience
- (2019) Martin Oft SEMINARS IN IMMUNOLOGY
- NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis
- (2019) Nour Ershaid et al. Nature Communications
- Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer
- (2019) Thomas A. Waldmann et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
- (2019) Sara K. Daniel et al. SEMINARS IN CANCER BIOLOGY
- A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
- (2019) Anfray et al. Cells
- IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer
- (2018) Te-Chia Wu et al. CANCER RESEARCH
- Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma
- (2018) Eudocia Q Lee et al. CLINICAL CANCER RESEARCH
- Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
- (2018) Brandon W. Higgs et al. CLINICAL CANCER RESEARCH
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
- (2018) David Linehan et al. JOURNAL OF CLINICAL ONCOLOGY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
- (2018) Sonia Pernas et al. LANCET ONCOLOGY
- Interleukin-6 and prostate cancer: Current developments and unsolved questions
- (2018) Zoran Culig et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
- (2018) Elise Alspach et al. Cold Spring Harbor Perspectives in Biology
- Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.
- (2018) Michael Carleton et al. JOURNAL OF CLINICAL ONCOLOGY
- NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
- (2018) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
- (2018) Youn H Kim et al. LANCET ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Perspectives on interferon-alpha in the treatment of Polycythemia vera and related Myeloproliferative neoplasms: minimal residual disease and cure?
- (2018) Hans Carl Hasselbalch et al. Seminars in Immunopathology
- Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study
- (2018) Nicolas Isambert et al. OncoImmunology
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
- (2018) Aung Naing et al. CANCER CELL
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- FADD at the Crossroads between Cancer and Inflammation
- (2018) Sara Mouasni et al. TRENDS IN IMMUNOLOGY
- Anakinra Therapy for Non-cancer Inflammatory Diseases
- (2018) Giulio Cavalli et al. Frontiers in Pharmacology
- Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
- (2018) Ahmad Tarhini et al. Journal for ImmunoTherapy of Cancer
- A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors
- (2018) Tiziano Ongaro et al. JOURNAL OF BIOTECHNOLOGY
- Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis
- (2017) Natalie J. Ives et al. EUROPEAN JOURNAL OF CANCER
- Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy
- (2017) Dejan Micic et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
- (2017) Chiara Berlato et al. JOURNAL OF CLINICAL INVESTIGATION
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
- (2017) Roger Chou et al. JOURNAL OF UROLOGY
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- (2017) Paul M Ridker et al. LANCET
- A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer
- (2017) Ravi Salgia et al. LUNG CANCER
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Family Cytokines
- (2017) Stefan Rose-John Cold Spring Harbor Perspectives in Biology
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Viral Therapy for Mesothelioma
- (2017) Daniel F. Pease et al. Frontiers in Oncology
- Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma
- (2016) M. Simonelli et al. ANNALS OF ONCOLOGY
- A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
- (2016) Megan C. Duggan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model
- (2016) Antonio Sacco et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
- (2016) S. Bo hm et al. CLINICAL CANCER RESEARCH
- Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
- (2016) Aung Naing et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
- (2016) John D. Hainsworth et al. Targeted Oncology
- TGF-β Family Signaling in the Control of Cell Proliferation and Survival
- (2016) Yun Zhang et al. Cold Spring Harbor Perspectives in Biology
- Targeting the CCL2-CCR2 signaling axis in cancer metastasis
- (2016) Su Yin Lim et al. Oncotarget
- A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
- (2016) Andrew S. Brohl et al. Journal for ImmunoTherapy of Cancer
- Interleukin-6 as a Therapeutic Target
- (2015) J.-F. Rossi et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
- (2015) L. W. Goff et al. CLINICAL CANCER RESEARCH
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
- (2015) Nicholas Butowski et al. NEURO-ONCOLOGY
- The immunocytokine NHS-IL12 as a potential cancer therapeutic
- (2015) Jonathan Fallon et al. Oncotarget
- Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- (2014) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Interleukin 12: still a promising candidate for tumor immunotherapy?
- (2014) Witold Lasek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
- (2014) M. D. Galsky et al. CLINICAL CANCER RESEARCH
- PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
- (2014) A. Necchi et al. INVESTIGATIONAL NEW DRUGS
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Cancer-related inflammation and treatment effectiveness
- (2014) Connie I Diakos et al. LANCET ONCOLOGY
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
- (2014) Koji Taniguchi et al. SEMINARS IN IMMUNOLOGY
- Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
- (2014) Irene Brana et al. Targeted Oncology
- High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
- (2014) Janice P Dutcher et al. Journal for ImmunoTherapy of Cancer
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
- (2014) Roxanne Payne et al. Journal for ImmunoTherapy of Cancer
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
- (2012) J. Emmerich et al. CANCER RESEARCH
- A review on CXCR4/CXCL12 axis in oncology: No place to hide
- (2012) Urszula M. Domanska et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
- (2012) Kenneth J. Pienta et al. INVESTIGATIONAL NEW DRUGS
- Paraneoplastic Thrombocytosis in Ovarian Cancer
- (2012) Rebecca L. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
- (2012) John H. Sampson et al. PLoS One
- Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
- (2011) B. B. Aggarwal et al. BLOOD
- IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
- (2011) John B. Mumm et al. CANCER CELL
- Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
- (2011) Jermaine Coward et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
- (2011) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-related inflammation: Common themes and therapeutic opportunities
- (2011) Frances R. Balkwill et al. SEMINARS IN CANCER BIOLOGY
- Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
- (2010) J. F. M. Jacobs et al. CLINICAL CANCER RESEARCH
- Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
- (2009) Andrew J. Rech et al. Annals of the New York Academy of Sciences
- Role of cytokine therapy for Renal Cell Carcinoma in the era of targeted agents
- (2009) Sebastien J. Hotte et al. Current Oncology
- The role of differential expression of human interferon-A genes in antiviral immunity
- (2009) Pierre Génin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
- (2008) E. R. Brown et al. ANNALS OF ONCOLOGY
- Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
- (2008) David S. Alberts et al. GYNECOLOGIC ONCOLOGY
- Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma
- (2008) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started